of LDL is determined in large part by its rate of uptake been identified by epidemiologic studies (Table 1) , elevated levels of serum cholesterol are probably unique through the hepatic LDL receptor pathway, as eviin being sufficient to drive the development of atherodenced by the fact that lack of functional LDL receptors sclerosis in humans and experimental animals, even in is responsible for the massive accumulation of LDL in the absence of other known risk factors. The elucidation patients with homozygous familial hypercholesterolof molecular mechanisms that control cholesterol bioemia (Goldstein and Brown, 1977). The expression of synthesis and serum cholesterol levels (reviewed in LDL receptors is subject to feedback control by intracelGoldstein and Brown, 1977) led to the development of lular cholesterol levels. Low levels of intracellular choles-"statins," a potent class of cholesterol lowering drugs terol lead to activation of the SREBP transcription facthat have been proven to significantly reduce cardiovastors, which stimulate transcription of the LDL receptor cular mortality in hypercholesterolemic patients (Gould gene and other genes involved in cholesterol biosynet al., 1998). However, available statins are not sufficient thesis (Brown and Goldstein, 1997). Statins lower circuto fully prevent the progression of atherosclerosis in lating cholesterol levels indirectly by inhibiting HMG many susceptible individuals. Indeed, even among indiCoA-reductase, the rate limiting enzyme required for viduals with the same cholesterol levels there is great endogenous cholesterol biosynthesis. The resulting dedisparity in the expression of clinical disease. This is crease in intracellular cholesterol leads to activation of most vividly illustrated by two subjects with the same SREBP, upregulation of LDL receptors, and enhanced founder gene defect leading to homozygous familial hyclearance from plasma degradation of LDL, reducing its percholesterolemia, and similarly elevated plasma chocirculating levels. lesterol levels. One, a male, died of coronary artery disTargeted disruption of the apo E or LDL receptor ease at age 3, while a female, despite developing genes, or overexpression of the human apo B gene in symptoms of cardiovascular disease, died of unrelated mice, results in marked increases in VLDL and/or LDL causes at age 33 (Hobbs et al., 1990 , 1997). The specific properties of press or lack genes of interest has led to a growing list of proteins that accelerate or retard the rate at which oxidized LDL (oxLDL), usually studied following oxidation of native LDL in vitro, depend on the extent of lesions develop, and/or alter lesion composition, examples of which are provided in Table 2 and described modification. This can range from "minimal" modification, (mmLDL) in which the LDL particle can still be throughout this review. The products encoded by these genes thus represent potential targets for therapeutic recognized by LDL receptors (Navab et al., 1996), to extensive oxidation, in which the apo B component is intervention in humans. It is important to note that the development of atherosclerosis in these murine models, fragmented and lysine residues are covalently modified with reactive breakdown products of oxidized lipids as in virtually all animal models of atherosclerosis, is driven by extreme elevations in circulating cholesterol (Steinberg and Witztum, 1999). Such particles are not bound by the LDL receptor, but rather by several solevels that result in the formation of extensive lesions . There is also evidence that macromice were crossed with RAG-1 recombinase-deficient phages may contribute directly to the availability of exmice, which eliminates both T and B cell compartments, tracellular cholesterol acceptors through secretion of and then fed cholesterol to achieve plasma cholesterol apo E (Linton et al., 1995), which is capable of contributlevels of 1600 mg/dl or greater, lesion formation was ing to the formation of HDL particles.
over a time scale of weeks to months. In contrast, the . The specific properties of press or lack genes of interest has led to a growing list of proteins that accelerate or retard the rate at which oxidized LDL (oxLDL), usually studied following oxidation of native LDL in vitro, depend on the extent of lesions develop, and/or alter lesion composition, examples of which are provided in Table 2 and described modification. This can range from "minimal" modification, (mmLDL) in which the LDL particle can still be throughout this review. The products encoded by these genes thus represent potential targets for therapeutic recognized by LDL receptors (Navab et al., 1996), to extensive oxidation, in which the apo B component is intervention in humans. It is important to note that the development of atherosclerosis in these murine models, fragmented and lysine residues are covalently modified with reactive breakdown products of oxidized lipids as in virtually all animal models of atherosclerosis, is driven by extreme elevations in circulating cholesterol (Steinberg and Witztum, 1999) . Such particles are not bound by the LDL receptor, but rather by several solevels that result in the formation of extensive lesions IFN␥ also stimulates macrophage production of proinmice revealed that many recognized epitopes of oxiflammatory cytokines and increases expression of MHC dized phospholipids either as free lipids or as protein class 2 molecules. Together, these effects of IFN␥ would adducts. These antibodies, mostly IgM, had the ability be predicted to increase accumulation of macrophages to block the binding and degradation of oxLDL by macwithin lesions and enhance their ability to present antirophages, suggesting that this epitope was a ligand for gen to T cells. The net effect of IFN␥ in mice is atherooxLDL uptake. Intriguingly, a genetic analysis of these genic, as apo E-deficient mice lacking the IFN␥ receptor antibodies revealed that they were 100% homologous (R0) exhibited significantly less atherosclerosis than to T15 natural antibodies to phosphorylcholine, which control apo E-deficient mice (Gupta et al., 1997) . Lesions provide optimal protection to mice against lethal infecwere less cellular and had decreased collagen content. tion with S. pneumoniae (Shaw et al., 2000) . Thus, these Recent studies suggest that the interaction of CD40 evolutionarily conserved antibodies, which are present ligand with its receptor promotes expression of a diverse even in mice raised in germ-free environments, were set of atherogenic molecules by macrophages, smooth probably selected for their ability to bind to oxidized muscle cells, and endothelial cells, including cytokines, membranes, and may have a protective role. matrix metalloproteinases, adhesion molecules and tisThese observations suggest that it might be possible sue factor (Mach et al., 1998a) Although it has been difficult to establish animal modities of metalloproteinases would be of potential clinical benefit. To date, animal models in which plaque rupture els of spontaneous acute myocardial infarction (i.e., not requiring direct interventions such as ligation of a coroand the coagulation system reliably contribute to lesion progression and acute thrombotic events have not been nary artery), the recent observation that it is possible to reproducibly induce myocardial infarctions in mice with developed. Variation in levels of several coagulation factors, including fibrinogen and factor VII, are associated combined LDL R and apo E deficiency by exposure to mental stress or hypoxia (Caligiuri et al., 1999) should with increased risk of cardiovascular disease (Table 1) . Extensive fibrin deposition is observed in most complex provide new opportunities for investigation of later stages of lesion development. While myocardial infarchuman lesions (Figure 3) , and decreased fibrinolytic activity has been proposed to accelerate arterial atherotions in this model do not appear to result from plaque rupture, the ischemic consequences of transient hypgenesis by facilitating thrombosis and fibrin deposition within developing atherosclerotic lesions (Lee and oxia could be prevented by treatment with an endothelin A receptor antagonist. These observations suggest an Libby, 1997). However, Apo E-deficient mice lacking fibrinogen develop lesions that are similar in size and important role of endothelin-dependent vasoconstriction in determining the extent of hypoxic injury that may complexity to control apo E-deficient mice (Xiao et al., 1998) . Similarly, LDL receptor-deficient mice lacking also be relevant to ischemic events resulting from coronary thrombosis. plasminogen activator inhibitor-1 (PAI-1), which inhibits the activator of plasminogen and thus should shift the balance toward greater fibrin hydrolysis, also develop Toward New Therapies As atherosclerosis is a chronic disease requiring lifetime typical atherosclerotic lesions (Sjoland et al., 2000) .
Neovascularization is prevalent in human atherosclepreventive therapy, new antiatherogenic drugs should meet the criteria of being safe, palatable, inexpensive rotic lesions associated with plaque rupture, hemor- and of significant benefit beyond currently available atherogenic effects comparible to those observed in animal models . Epidemiologic studies linking 15-LO therapies. Small molecule-based approaches targeting enzymes or signal-dependent transcription factors are expression levels or specific 15-LO polymorphisms to risk of atherosclerosis could provide helpful information thus much more likely to be of general clinical utility than approaches requiring the delivery of genes or polyalong these lines. A challenge in carrying out intervention studies in humans is the need to link a measurable peptides. Multiple steps in the atherogenic process could theoretically serve as the basis for intervention, parameter of the inhibitor's activity with disease outcome. In the case of statins, effectiveness of inhibition including steps that control LDL levels and LDL oxidation, monocyte recruitment, scavenger receptor expresof HMG CoA reductase activity was readily assessed by measurement of serum cholesterol levels, reductions sion and reverse cholesterol transport (Table 4) . We consider here selected examples of potential targets for new of which were highly correlated with reductions in atherosclerotic complications. In contrast, the relevant site classes of antiatherogenic drugs that illustrate some of the opportunities and practical challenges that lie of action of 15-LO inhibitors (as well as some of the other potential targets listed in Table 4) 
